| InChI |
InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
|
| Synonyms |
sulfadiazine; 68-35-9; Sulphadiazine; Sulfapyrimidine; Sulfadiazin; Adiazine; Sulfazine; Sulfadiazene; Adiazin; Debenal; Pyrimal; Liquadiazine; Sulfapyrimidin; 2-Sulfanilamidopyrimidine; Coco-Diazine; Cremodiazine; Spofadrizine; Theradiazine; Cremotres; Deltazina; Diazolone; Eskadiazine; Microsulfon; Neotrizine; Palatrize; Piridisir; Quadetts; Quadramoid; Sanodiazine; Sterazine; Sulfatryl; Sulfolex; Sulfonsol; Terfonyl; Trifonamide; Truozine; Diazin; Neazine; Pirimal; Sulfose; Trisem; Sulfanilamidopyrimidine; Honey diazine; Lipo-Levazine; Tri-Sulfameth; Triple Sulfas; Lipo-Diazine; Metha-Meridiazine; Sulfadiazinum; Diazovit; Sulfadiazina; Sulphadiazine E; 4-amino-N-(pyrimidin-2-yl)benzenesulfonamide; Sulfapirimidin; Di-Azo-Mul; Thi-Di-Mer; 2-Sulfanilylaminopyrimidine; Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-; Codiazine; Silvadene; Pecta-diazine, suspension; 4-amino-N-pyrimidin-2-ylbenzenesulfonamide; RP 2616; Pyrimidine, 2-sulfanilamido-; 2-Sulfapyrimidine; N(1)-2-pyrimidylsulfanilamide; N(1)-2-pyrimidinylsulfanilamide; 4-AMINO-N-2-PYRIMIDINYLBENZENESULFONAMIDE; N(sup 1)-2-Pyrimidinylsulfanilamide; 4-amino-N-(pyrimidin-2-yl)benzene-1-sulfonamide; Sulfanilamide, N1-2-pyrimidinyl-; 4-amino-N-pyrimidin-2-yl-benzenesulfonamide; CHEBI:9328; Sulfanilamide, N(sup 1)-2-pyrimidinyl-; 4-Amino-N-2-pyrimidinyl-benzenesulfonamide; N(sup1)-2-Pyrimidylsulfanilamide; Sulfanilamide, N1-2(1H)-pyrimidinylidene-; silver sulfadiazine; A-306; N(sup1)-2-Pyrimidinylsulfanilamide; CHEMBL439; S. N. 112; NSC35600; NSC-35600; CAS-68-35-9; NCGC00016305-01; Solfadiazina; CocoDiazine; Solfadiazina [DCIT]; Sulfadiazine 100 microg/mL in Acetonitrile; 0N7609K889; 2-Sulfanilamidopyrimidin; NSC117870; Sulfapyrimidin [German]; SDZ; Sulfadiazinum [INN-Latin]; Sulfadiazina [INN-Spanish]; Sildaflo; S.N. 112; 2-Sulfanilamidopyrimidin [German]; A-306 (VAN); 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide; A 306; SMR000059113; Sulfadiazine (TN); N-(2-Pyrimidinyl)sulfanilamide; rBPI21 & Sulfa; RP-2616; SR-01000002973; SSD; EINECS 200-685-8; MFCD00006065; NSC 35600; 2-Sulfanilamido-pyrimidine; BRN 0235192; diazine; CRL-8131 & Sulfadiazine; N1-2-Pyrimidinylsulfanilamide; Sulfadiazine (JAN/USP/INN); AI3-01047; Sulfadiazine,(S); Trisulfapyrimidine, oral suspension; UNII-0N7609K889; Sulfadiazine [USP:INN:BAN:JAN]; Prestwick_428; Spectrum_000986; Sulfadiazina Reig Jofre; Sulfacombin (Salt/Mix); Prestwick0_000023; Prestwick1_000023; Prestwick2_000023; Prestwick3_000023; Spectrum2_001319; Spectrum3_001362; Spectrum4_000342; Spectrum5_000992; SULFADIAZINE [MI]; [(4-aminophenyl)sulfonyl]pyrimidin-2-ylamine; SULFADIAZINE [INN]; SULFADIAZINE [JAN]; Epitope ID:140083; N1-2-Pyrimidylsulfanilamide; Sulfadiazine, >=99.0%; DSSTox_CID_24130; DSSTox_RID_80105; SULFADIAZINE [VANDF]; DSSTox_GSID_44130; Oprea1_081078; SCHEMBL24176; BSPBio_000085; BSPBio_002884; KBioGR_000743; KBioSS_001466; SULFADIAZINE [MART.]; 5-25-10-00067 (Beilstein Handbook Reference); MLS000069423; MLS006011457; DivK1c_000543; SPECTRUM1500546; SULFADIAZINE [USP-RS]; SULFADIAZINE [WHO-DD]; SPBio_001417; SPBio_002006; BPBio1_000095; WLN: T6N CNJ BMSWR DZ; DTXSID7044130; HMS501L05; KBio1_000543; KBio2_001466; KBio2_004034; KBio2_006602; KBio3_002104; SULFADIAZINE [GREEN BOOK]; NINDS_000543; GLXC-25873; HMS1568E07; HMS1921A13; HMS2090P09; HMS2092I15; HMS2095E07; HMS2235D19; HMS3371L19; HMS3655I10; HMS3712E07; Pharmakon1600-01500546; SULFADIAZINE [ORANGE BOOK]; ZINC120319; SULFADIAZINE [EP MONOGRAPH]; SULFADIAZINE [USP IMPURITY]; ALBB-014888; AMY33423; BCP12140; HY-B0273; SULFADIAZINE [USP MONOGRAPH]; Tox21_110360; BBL013169; BDBM50166571; CCG-39257; NSC757324; Recombinant bactericidal/permeability-increasing protein & Sulfadiazine; s1770; STK317797; SULFOSE COMPONENT SULFADIAZINE; TERFONYL COMPONENT SULFADIAZINE; 2-(p-Aminobenzenesulfonamido)pyrimidin; AKOS000119073; LANTRISUL COMPONENT SULFADIAZINE; SULFALOID COMPONENT SULFADIAZINE; DB00359; KS-1144; NSC-757324; 2-(4-Aminobenzenesulfonamido)pyrimidine; 4-amino-N-2-pyrimidylbenzenesulfonamide; IDI1_000543; NEOTRIZINE COMPONENT SULFADIAZINE; SULFADIAZINE COMPONENT OF SULFOSE; NCGC00016305-02; NCGC00016305-03; NCGC00016305-04; NCGC00016305-05; NCGC00016305-06; NCGC00016305-09; NCGC00016305-10; NCGC00016305-11; NCGC00023291-03; NCGC00023291-04; SULFADIAZINE (TRISULFAPYRIMIDINES); SULFADIAZINE COMPONENT OF TERFONYL; TRISULFAPYRIMIDINES (SULFADIAZINE); 2-(4-Aminobenzenesulfonylamino)pyrimidine; AC-26817; SULFADIAZINE COMPONENT OF LANTRISUL; SULFADIAZINE COMPONENT OF SULFALOID; 4-amino-N-2-pyrimidinyl benzenesulfonamide; SBI-0051520.P003; SULFADIAZINE COMPONENT OF NEOTRIZINE; TRIPLE SULFOID COMPONENT SULFADIAZINE; 4-[[(Pyrimidin-2-yl)amino]sulfonyl]aniline; AB00052095; Benzenesulfonamide,4-amino-N-2-pyrimidinyl-; FT-0674739; FT-0674740; FT-0674741; S0579; Sulfadiazine 1000 microg/mL in Acetonitrile; Sulfadiazine for identification of impurity F; SW196657-3; 4-amino-N-(2-pyrimidinyl) benzenesulfonamide; EN300-19076; SULFADIMIDINE IMPURITY B [EP IMPURITY]; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide #; 68S359; C07658; D00587; D92267; SULFADIAZINE COMPONENT OF TRIPLE SULFOID; Trisulfapyrimidine, oral suspension (Salt/Mix); AB00052095-13; AB00052095-14; AB00052095_15; AB00052095_16; Benzenesulfonamide, 4-amino-N-(2-pyrimidinyl)-; Sulfadiazine, VETRANAL(TM), analytical standard; A836115; Q-201759; Q2555060; SR-01000002973-2; SR-01000002973-3; BRD-K32273377-001-05-4; BRD-K32273377-001-09-6; F1657-1720; Sulfadiazine, certified reference material, TraceCERT(R); TRISULFAPYRIMIDINES (SULFADIAZINE) [ORANGE BOOK]; Z104472626; Sulfadiazine, European Pharmacopoeia (EP) Reference Standard; Sulfadiazine, United States Pharmacopeia (USP) Reference Standard; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide, N1-(Pyrimidin-2-yl)sulfanilamide; Sulfadiazine, Pharmaceutical Secondary Standard; Certified Reference Material; 141582-64-1; Sulfadiazine for identification of impurity F, European Pharmacopoeia (EP) Reference Standard
|
